Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

References for PMC Articles for PubMed (Select 3923849)

1.

Medical importance of measles.

LANGMUIR AD.

Am J Dis Child. 1962 Mar;103:224-6. No abstract available.

PMID:
14462174
2.

Cost-benefits of measles eradication: effects of a federal intervention.

Albritton RB.

Policy Anal. 1978 Winter;4(1):1-21.

PMID:
10313842
3.

Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines.

Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR.

Proc Soc Exp Biol Med. 1980 Nov;165(2):260-3. No abstract available.

PMID:
7443713
4.

Hospitalizations for measles, 1970-78.

Nolan TF Jr, Goodman RA, Patriarca PA, Hinman AR.

Am J Public Health. 1982 Sep;72(9):1037-9.

5.
6.

Rubella vaccination in the United States: a ten-year review.

Preblud SR, Serdula MK, Frank JA Jr, Brandling-Bennett AD, Hinman AR.

Epidemiol Rev. 1980;2:171-94. Review. No abstract available.

PMID:
7000534
7.

Benefits, risks and costs of viral vaccines.

Koplan JP, Axnick NW.

Prog Med Virol. 1982;28:180-91. Review. No abstract available.

PMID:
6806868
8.

The economic value of life: linking theory to practice.

Landefeld JS, Seskin EP.

Am J Public Health. 1982 Jun;72(6):555-66.

9.

A benefit-cost analysis of mumps vaccine.

Koplan JP, Preblud SR.

Am J Dis Child. 1982 Apr;136(4):362-4.

PMID:
6803581
10.

Combined live measles, mumps, and rubella virus vaccines.

Buynak EB, Weibel RE, Whitman JE Jr, Stokes J Jr, Hilleman MR.

JAMA. 1969 Mar 24;207(12):2259-62. No abstract available.

PMID:
5818433
11.

Combined live measles, mumps, rubella vaccine. Immunological response.

Krugman S, Muriel G, Fontana VJ.

Am J Dis Child. 1971 May;121(5):380-1. No abstract available.

PMID:
5091532
12.

Benefits due to immunization against measles.

Axnick NW, Shavell SM, Witte JJ.

Public Health Rep. 1969 Aug;84(8):673-80. No abstract available.

13.

Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines.

Krugman RD, Witte JJ, Parkman PD, Herrmann KL, Meyer HM Jr, Wende RD, Meyer BC, Dungca R.

Public Health Rep. 1977 May-Jun;92(3):220-2. No abstract available.

14.

Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis.

Modlin JF, Jabbour JT, Witte JJ, Halsey NA.

Pediatrics. 1977 Apr;59(4):505-12.

PMID:
850592
15.

Benefit-cost analysis of rubella vaccination policy.

Schoenbaum SC, Hyde JN Jr Bartoshesky L, Crampton K.

N Engl J Med. 1976 Feb 5;294(6):306-10.

PMID:
813141
16.

The benefits from 10 years of measles immunization in the United States.

Witte JJ, Axnick NW.

Public Health Rep. 1975 May-Jun;90(3):205-7. No abstract available.

17.

Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.

Schwarz AJ, Jackson JE, Ehrenkranz NJ, Ventura A, Schiff GM, Walters VW.

Am J Dis Child. 1975 Dec;129(12):1408-12.

PMID:
128287
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk